Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 4;24(7):6746. doi: 10.3390/ijms24076746

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

CypD KO mitigates the sevoflurane-induced increases of ROS, decreases of DCX, and inhibition of cell migration in NPCs. (A) The sevoflurane treatment does not increase ROS levels compared to the control condition in NPCs harvested from CypD KO mice. Quantitative Western blot (B,C) analysis shows that the sevoflurane treatment does not decrease DCX levels compared to the control condition in the NPCs harvested from CypD KO mice. There is no significant difference in β-actin levels between each condition. (D) The representative transwell assay images of migrated cell stained by crystal violet (top) or DAPI (below) at 24 h after the sevoflurane treatment. (E) Quantification of the transwell assay shows that the sevoflurane treatment does not significantly affect the number of migrated NPCs harvested from CypD KO mice compared to the control condition. N = 6–8 in each group. Student’s t-test was used to analyze the data. N.S: non-significant differences.